ESMO

Phase 3 Trial of Lurbinectedin vs Pegylated Liposomal Doxorubicin or Topotecan in Platinum-Resistant Ovarian Cancer Patients
Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer.
Read More
Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab vs Carboplatin/Gemcitabine/Bevacizumab in Patients with Recurrent Ovarian Cancer
The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile.
Read More
Psychological Support vs Standard of Care Following Chemotherapy for Ovarian Cancer
Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support.
Read More
Page 3 of 3
Results 21 - 23 of 23